

STRUCTURAL EXPLORATION AND
PHARMACOPHORIC INVESTIGATION OF SAHA BASED
HDAC INHIBITORS AS ANTICANCER AGENT

A
Thesis

Submitted for
Partial fulfilment of the requirement for the award of degree
of

MASTER OF PHARMACY
(PHARMACEUTICAL CHEMISTRY)



SESSION 2021-22

SUPERVISED BY:

Dr. HARISH RAJAK

M. Pharm., Ph.D

Assistant Professor

(Pharmaceutical Chemistry)

SUBMITTED BY:

RAKESH KUMAR KORE

Roll No. 20703008

Enroll No. GGV/16/6157

M. PHARM. SEM IV

DEPARTMENT OF PHARMACY
GURU GHASIDAS VISHWAVIDYALAYA BILASPUR (C.G.)



DEPARTMENT OF PHARMACY

GURU GHASIDAS VISHWAVIDYALAYA BILASPUR (C.G.)

(A Central University Established by the Central University Act-2009.No-25 of 2009)

Tel. No. 07752-260027; Fax No. 07752-260148

CERTIFICATE

This is to certify that **Mr. Rakesh Kumar kore** student of M.Pharm. Semester-IV, Department of Pharmacy has submitted his synopsis entitled “**Structural Exploration and Pharmacophoric Investigation of SAHA Based HDAC Inhibitors as Anticancer Agent**” for the partial fulfillment of the requirement for the degree of **Master of Pharmacy (Pharmaceutical Chemistry)**. He has completed his project under the supervision of **Dr. Harish Rajak** (Asst. Prof). His work is original, satisfactory and is not submitted anywhere else for the award of any degree.

I hereby forward the project to the Vishwavidyalaya for award of degree of the Master of Pharmacy (Pharmaceutical Chemistry) for the session 2021 – 2022.

Forwarded by-

(Head of department)
Head

Department of Pharmacy
Guru Ghasidas Vishwavidyalaya
(A Central University)
Bilaspur (C.G.)



DEPARTMENT OF PHARMACY

GURU GHASIDAS VISHWAVIDYALAYA BILASPUR (C.G.)

(A Central University Established by the Central University Act-2009 No-25 of 2009)

Tel. No. 07752-260027; Fax No. 07752-260148

CERTIFICATE

This is to certify that **Mr. Rakesh Kumar kore** student of M. Pharm. Semester-IV, Department of pharmacy has submitted his project entitled “**Structural Exploration and Pharmacophoric Investigation of SAHA Based HDAC Inhibitors as Anticancer Agent**” for the partial fulfillment of the requirement for the degree of **Master of Pharmacy (Pharmaceutical Chemistry)**. He has completed his project under the supervision of **Dr. Harish Rajak** (Asst. Prof). His work is original, satisfactory and is not submitted anywhere else for the award of any degree.

I hereby forward the project to the Vishwavidyalaya for award of degree of the Master of Pharmacy (Pharmaceutical Chemistry) for the session 2021 – 2022.

Supervisor

Dr. HARISH RAJAK

(Asst. Professor)



DEPARTMENT OF PHARMACY

GURU GHASIDAS VISHWAVIDYALAYA BILASPUR (C.G.)

(A Central University Established by the Central University Act-2009 No-25 of 2009)

Tel. No. 07752-260027; Fax No. 07752-260148

DECLARATION

I hereby declare that the project entitled “**Structural Exploration and Pharmacophoric Investigation of SAHA Based HDAC Inhibitors as Anticancer Agent**” was done by me. The entire work was done with the guidance and suggestions received from my supervisor **Dr. Harish Rajak** (Asst. Prof.) for the partial fulfillment of the requirement for the Degree of Master of Pharmacy (Pharmaceutical Chemistry).

Date :


(Rakesh kumar kore)

Place :

M. Pharm Sem. IV

ACKNOWLEDGEMENT

Throughout the process of writing this dissertation, I received a lot of help and support. I'd like to express my gratitude to those individuals without whom I would not have been able to accomplish my research or complete my master's degree. First and foremost, I would like to thank the Lord "Almighty God" for providing wisdom, strength, tolerance, and knowledge in investigating things, for guiding us in overcoming all the challenges I faced and for making this research possible.

I would like to express my sincere gratitude to my supervisor, **Dr. Harish Rajak** Asst. Prof. (Pharmaceutical Chemistry), Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur (C.G.), a person of enormous knowledge and polite behaviour. He has been supportive from the first day I started working with him; his motivation, direction, and overall insights into this area have made this an inspiring experience for me. I cannot express my feelings in words about how he encouraged and helped me during my project work. He continuously gave his valuable guidance and remained with me despite his hectic schedule. I am highly gratified to **Guru Ghasidas Vishwavidyalaya** and **Dr. Bharti Ahirwar** Head of the Department of Pharmacy, for approving me to undertake my research work and ensuring all necessary facilities and guidance. This has been a lovely experience at the Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur, at which teaching and non-teaching staff have always been inclined to assist whenever required. I'd also want to convey my gratefulness to our laboratory and library staff, who has given me a wonderful working atmosphere and diligent support throughout the research.

I finally owe my gratitude to my loving parents, **Mr. Tijau ram kore**, **Mrs. Jaisheela kore** and my brother **Mukesh kore** for their wonderful gestures and unconditional support, which have enriched my life with love and joy.

I would like to express my extreme thanks to my seniors **Mr. Vijay Patel** and **Ekta Shirbhate** for their valuable guidelines and my batch mates especially **Priya**, **Padum**, **Kamal**, **Nidhi**, **Tripti**, **Rekha**, **Sunil**, for spreading a good working atmosphere in the laboratory all this contribution in some way to the success of this research work, allowing me to attain this a milestone in my life's journey.

List of Tables

S.No.	Title
1	Global status of cancer new cases, and deaths for 36 cancers and all cancers combined in 2020.
2	Classification and Key Characteristics of HDAC
3	Classification and Specificity of HDAC inhibitors
4	FDA Approved HDAC Inhibitor Drugs
5	Structures and PIC ₅₀ values of the HDAC inhibitors.
6	Interaction pattern of identified compound after XP molecular docking with protein 4lxz.
7	Interaction pattern of identified compound after XP molecular docking with protein 4ly1.
8	Interaction pattern of identified compound after XP molecular docking with protein 5iwg.
9	Interaction pattern of identified compound after XP molecular docking with protein 5ixo.
10	Top 10 selected hypotheses generated by PHASE
11	Data field-based QSAR model
12	Statistics result of field-based QSAR models (Internal Validation)
13	Experimental and predicted activity of dataset ligands, obtained from generated atom-based 3D-QSAR model.
14	Statistics result of atom-based QSAR models (Internal Validation and PLS Analyses)
15	ADMET Analysis

CONTENT

S.No.	Title	Page no.
1	CHAPTER 01 INTRODUCTION	1
1.1	Drug discovery and development	1-1
1.1.1	Structure-based drug design	2-5
1.1.2	Ligand-based drug design	6-9
1.2	Cancer	10-10
1.2.1	Types of cancer	10-11
1.2.2	Cause of cancer	11-12
1.2.3.	Global Status of Cancer	13-14
1.2.4	Diagnosis of cancer	15-15
1.2.5	Treatment of cancer	16-17
1.3	Chromatin and Histone	17-17
1.3.1	Chromatin, structure, biochemistry, and function	18-18
1.3.2	Histone modification and treatment	18-18
1.3.3	Histone deacetylase	18-18
1.3.4	Classification of HDAC	18-18
1.3.5	Histone Deacetylase 2	19-19
1.4	Histone deacetylase Inhibitors	20-21
1.4.1	Mechanism of HDAC inhibitors	22-22
	Reference	23-31
2	CHAPTER 02 LITERATURE REVIEW	32-36
2.1	Reference	37-38
3	CHAPTER 03 PLAN OF WORK	39-39
3.1	RESEARCH ENVISAGED	39-39
3.2	OBJECTIVES	39-39
3.3	PLAN OF WORK	40-40
4	CHAPTER 04 MATERIAL AND METHOD	41-41
4.1	Preparation of data set	41-41
4.2	Protein preparation	41-52
4.3	Ligand preparation	53-53
4.4	Receptor Grid generation	53-53
4.5	Docking	54-54
4.6	Pharmacophore modelling and 3D QSAR model generation	54-54
4.7	ADME and drug likeness	55-55
	Reference	56-58
5	CHAPTER 05 RESULT AND DISCUSSION	59-91
6	CHAPTER 06 COCLUSION	92-92

List of Figures

S.No	Title
1	Categories of CADD
2	Types of cancer
3	Causes of cancer
4	Diagnosis of cancer
5	Types of cancer treatment
6	Mechanism of HDAC inhibitors
7	Binding interaction of ligand 12 with protein 4lxz
8	2D interaction of ligand 12 with protein 4lxz.
9	Binding interaction of ligand 48 with protein 4ly1.
10	2D interaction of ligand 48 with protein 4ly1.
11	Binding interaction of ligand 50 with protein 5iwg
12	2D interaction of ligand 50 with protein 5iwg.
13	Binding interaction of ligand 51 with protein 5ixo.
14	2D interaction of ligand 51 with protein 5ixo
15	Pharmacophore model ADDHR1
16	Gaussian steric interaction of Ligand 44.
17	Scatter plot of activity vs predicted activity
18	Hydrogen bonds donor interaction
19	Hydrophobic interaction
20	Electron withdrawing group interaction
21	Scatter plot of activity vs predicted activity